MRKMerck Sharp & Dohme LLCFinished
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Esophageal Squamous Cell Carcinoma (ESCC) · Gastroesophageal Junction Carcinoma (GEJC) · Esophageal Adenocarcinoma (EAC)
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 703 (final count)
- Started
- Feb 28, 2020
- Main results expected
- Jan 21, 2026
- Fully finished
- Jun 26, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event-free Survival (EFS)
Measured over: Up to ~60 months
Overall Survival (OS)
Measured over: Up to ~72 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04210115 · record last updated 2026-10-30 · checked 2026-11-09 15:47 UTC